University of Crete (UOC)
Φαρμακογενωμική στα αδενοκαρκινώματα πνεύμονα: Μελέτη των RRM1, RRM2, BRCA1 σαν προβλεπτικοί παράγοντες απάντησης στη θεραπεία πρώτης γραμμής με docetaxel-gemcitabine: Κλινική αξιολόγηση της αποτελεσματικότητας της ανωτέρω θεραπείας στους ηλικιωμένους.
Abstract
dc:descriptionAim 1: A phase II study was conducted in order to evaluate the efficacy of docetaxel/gemcitabine (DG) combination in elderly patients with lung adenocarcinomas. Seventy seven patients were enrolled. One (1.3%) complete and 23 (29.9%) partial responses were achieved (intention to treat analysis OR 31.2% 95% CI 20.82-41.51%) whereas tumor growth control was achieved in 53.3% of patients. The median TTP was 4.1 months, the median overall survival 9.4 months and the 1 and 2 year survival rate 37.9% and 10.7%. The DG regimen is an active and well tolerated front line chemotherapy for elderly patients with lung adenocarcinomas. Aim 2a: The mRNA expression of RRM1 and RRM2 in tumours from lung adenocarcinoma patients treated with docetaxel/gemcitabine was assessed and the results correlated with clinical outcome. RMM1 and RMM2 mRNA levels were determined by quantitative real time. PCR Amplification was successful in 42 (79%) of 53 enrolled patients. Low levels of RRM2 mRNA were associated with response to treatment (P=0.001). Patients with the lowest expression levels of RRM1 had a significantly longer time to progression (P=0.044) and overall survival (P=0.02) than patients with the highest levels. Patients with low levels of both RRM1 and RRM2 had a significantly higher response rate (60 vs 14.2% P=0.049) time to progression (9.9 vs 2.3 months P=0.003) and overall survival (15.4 vs 3.6 P=0.031) than patients with high levels of both RRM1 and RRM2 RRM1 and RRM2 mRNA expression in lung adenocarcinoma tumours is associated with clinical outcome to docetaxel/gemcitabine. Aim 2b: We have retrospectively examined the effect of RRM1, RRM2 and BRCA1 expression on outcome to gemcitabine plus docetaxel in advanced non-small cell lung cancer (NSCLC) patients. Tumor samples were collected from 102 chemotherapy naive advanced NSCLC patients. RRM1, RRM2 and BRCA1 mRNA levels were assessed by quantitative PCR and correlated with response time to progression and survival. As BRCA1 levels increased the probability of response increased (OR 1.09, p=0.01) and the risk of progression decreased (HR 0.99, p=0.36). As RRM1 and RRM2 levels increased the probability of response decreased (RRM1 OR 0.97, p=0.82, RRM2 OR 0.94 p=0.0001) and the risk of progression increased (RRM1, HR 1.02 p=0.001, RRM2 HR 1.005 p=0.01). An interaction observed between BRCA1 and RRM1 allowed patients to be classified in three risk groups according to combinations of gene expression levels with times to progression of 10.13, 4.17 and 2.30 months (p=0.001). Low BRCA1 expression was the only factor significantly associated with longer time to progression in 31 patients receiving cisplatin based second line therapy. The mRNA expression of BRCA1, RRM1 and RRM2 is potentially a useful tool for selecting NSCLC patients for individualized chemotherapy.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Boukovinas, Ioannis
- Μπουκοβίνας, Ιωάννης
Subjects
dc:subject × 13Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/25085